Design, synthesis and pharmacokinetic evaluation of a novel series of triazole-based Src kinase inhibitors with anti-proliferative activity

Letters in Drug Design and Discovery

Volumn 8, Issue 1, 2011, Pages 9-13

  Chen, Shaojun ^a   Guo, Chuansheng ^b   Shi, Shiting ^b   Shi, Yanyan ^b   Fang, Du ^a   Fan, Houxing ^b  

^a HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

^b Shanghai Sun Sail Pharmaceutical Science and Technology Co Ltd   (China)

Author keywords

Anti proliferative activity; Biological activity; SKI 606; Src Kinase; Synthesis; Triazoly group

Indexed keywords

ANTIMITOTIC AGENT; BOSUTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 78650899925     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011793663930     Document Type: Article

References (14)

1. Thomas, S M.; Brugge, J S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol., 1997, 13, 513-609.
2. Brunton, V G.; Frame, M C. Src and focal adhesion kinase as therapeutic targets in cancer. Curr. Opin. Pharmacol., 2008, 8, 427-432.
3. Yeatman, T. J. A renaissance for SRC. Nat. Rev. Cancer, 2004, 4, 470-480.
4. Frame, M. C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta, 2002, 1602, 114-130.
5. Susva, M.; Missbach, M.; Green. Src inhibitors: drugs for the treatment of osteoporosis cancer or both? J. Trends Pharmacol. Sci., 2000, 2 (12), 489-495.
6. Paul, R.; Zhang, Z. G.; Eliceiri, B. P.; Jiang, Q.; Boccia, A. D.; Zhang, R. L.; Chopp, M.; Cheresh, D. A. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med., 2001, 7, 222-227.
7. Weis, S.; Shintani, S.; Weber, A.; Kirchmair, R.; Wood, M.;Cravens, A.; McSharry, H.; Iwakura, A.; Yoon, Y. -S.; Himes, N.; Burstein, D.; Doukas, J.; Soll, R.; Losordo, D.; Cheresh, D. Srcblockade stabilizes a Flk/cadgerin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest., 2004, 113, 885-894.
8. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem., 2004, 47(27), 6658-6661.
9. Hennequin, L.F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T.P.; Lambert-van der Brempt, C.; Morgentin, R.; Norman, R.A.; Olivier, A.; Otterbein, L.; Plao, P.A.; Warin, N.; Costello, G. N-(5-chloro-1,3-benzodioxol- 4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy) quinazolin-4-amine, a novel, hirhly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem., 2006, 49(22), 6465-6488.
10. Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.; Johnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-Phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem., 2001, 44(23), 3965-3977. (Pubitemid 33051486)
11. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S. E.; Ple, P. A.; Lohmann, J-J. M.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Curwen, J. O.; Kendrew, J.; Lambert-van der Brempt, C. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J. Med. Chem., 1999, 42(26), 5369-5389.
12. Boschelli, D.H.; Wu, B.; Ye, F.; Wang, Y.; Golas, J.M.; Lucas, J.; Boschelli, F. Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J. Med. Chem., 2006, 49(26), 7868-7876.
13. Chen, Y.; Lopez-Sanchez, M.; Savoy, D.N.; Billadeau, D.D.; Dow, G.S.; Kozikowski, A.P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J. Med. Chem., 2008, 51(12),3437-3448.
14. Plé, P. A.; Green, T. P.; Hennequin, L. F.; Curwen, J.; Fennell, M.; Allen, J.; Lambert-van der Brempt, C.; Costello, G. Discovery of a new class of anilinoquinazoline inhibitor with high affinity and specifity for the tyrosine kinase domain of c-Src. J. Med. Chem. 2004, 47(4), 871-887.